Program
remibrutinib
Also written as “Remibrutinib”, “LOU064” and “LOU064 (blinded)”.
Its studies are mostly in Chronic Urticaria · Hidradenitis Suppurativa · Pruritus · Rosacea · Food Hypersensitivity, led by Novartis.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 3421 open or running | phase 3since Aug 19, 2021 | Dec 14, 2015 | Feb 22, 2027phase 3 · NCT06868212 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Dec 14, 2015.
- Dec 17, 2024Phase 3 study in Myasthenia GravisNCT06744920 · 180 enrolled · United States, Argentina, Australia and more
- Jan 23, 2025Phase 3 study in Hidradenitis SuppurativaNCT06799000 · 588 enrolled · United States, Argentina, Australia and more
- Feb 17, 20252 phase 3 studiesNCT06840392, NCT06846281
- Mar 6, 2025Phase 3 study in Chronic UrticariaNCT06868212 · 409 enrolled · United States
- Mar 6, 2025Phase 2 study in Chronic UrticariaNCT06865651 · 44 planned · United States, France, Germany and more
- Jun 19, 2025Phase 1 study in Renal InsufficiencyNCT07032272 · 16 enrolled · United States
- Nov 4, 2025Phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT07225504 · 1,275 planned · United States, Argentina, Australia and more
- Mar 3, 2026Phase 3 study in Indication of the Parent ProtocolNCT07456891 · 650 planned · Bulgaria, Canada, Colombia and more
- Jun 18, 2026Phase 3 study in Hidradenitis SuppurativaNCT07665437 · 710 planned · United States, Argentina, Australia and more
- Jun 26, 2026Phase 2 study in RosaceaNCT07681271 · 100 planned · United States, Bulgaria, Canada and more
- Jul 7, 2026Phase 3 study in Chronic Pruritus of Unknown OriginNCT07700056 · 180 planned · United States, Argentina, Canada and more
- Aug 12, 2026Phase 3 study in Food HypersensitivityNCT07768371 · 576 planned · United States
- Sep 4, 20262 phase 3 studiesNCT07811869, NCT07816328
- Sep 28, 2026Phase 1 study in Hidradenitis SuppurativaNCT07855276 · 30 planned · United States
Ahead
- Nov 3, 2026Primary completion: phase 3 study in Chronic UrticariaNCT05677451
- Feb 22, 2027Primary completion: phase 3 study in Chronic UrticariaNCT06868212
- May 17, 2027Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06799000
- Jun 3, 2027Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06840392
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07855276Hidradenitis Suppurativa · United States | 1 | Recruiting | Nov 29, 2027 | 30 |
| NCT07816328Chronic Urticaria · Canada, Hong Kong, Japan and more | 3 | Recruiting | May 24, 2028 | 382 |
| NCT07811869Chronic Pruritus of Unknown Origin · United States, Canada, China | 3 | Recruiting | Feb 26, 2029 | 180 |
| NCT07768371Food Hypersensitivity · United States | 3 | Recruiting | Mar 30, 2029 | 576 |
| NCT07700056Chronic Pruritus of Unknown Origin · United States, Argentina, Canada and more | 3 | Recruiting | Dec 19, 2029 | 180 |
| NCT07681271Rosacea · United States, Bulgaria, Canada and more | 2 | Recruiting | Dec 7, 2027 | 100 |
| NCT07665437Hidradenitis Suppurativa · United States, Argentina, Australia and more | 3 | Recruiting | Oct 15, 2031 | 710 |
| NCT07456891Indication of the Parent Protocol · Bulgaria, Canada, Colombia and more | 3 | Recruiting | Jan 30, 2033 | 650 |
| NCT07225504Multiple Sclerosis, Chronic Progressive · United States, Argentina, Australia and more | 3 | Recruiting | Dec 3, 2030 | 1,275 |
| NCT07032272Renal Insufficiency · United States | 1 | Completed | Oct 12, 2025 | 16 |
| NCT06868212Chronic Urticaria · United States | 3 | Active, not recruiting | Feb 22, 2027 | 409 |
| NCT06865651Chronic Urticaria · United States, France, Germany and more | 2 | Recruiting | Aug 23, 2027 | 44 |
| NCT06846281Relapsing Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Recruiting | Jul 25, 2029 | 400 |
| NCT06840392Hidradenitis Suppurativa · United States, Argentina, Austria and more | 3 | Active, not recruiting | Jun 3, 2027 | 565 |
| NCT06799000Hidradenitis Suppurativa · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 17, 2027 | 588 |
| NCT06744920Myasthenia Gravis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 25, 2028 | 180 |
| NCT06042478Chronic Urticaria · Argentina, Brazil, Bulgaria and more | 3 | Active, not recruiting | Sep 17, 2025 | 470 |
| NCT05976243Chronic Inducible Urticaria · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 11, 2026 | 362 |
| NCT05795153Chronic Urticaria · United States, Argentina, Canada and more | 3 | Completed | Apr 25, 2024 | 144 |
| NCT05677451Chronic Urticaria · United States, Argentina, Canada and more | 3 | Active, not recruiting | Nov 3, 2026 | 100 |
| NCT05753592Hepatic Impairment · Hungary | 1 | Completed | Dec 14, 2023 | 38 |
| NCT05513001Chronic Urticaria · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 26, 2024 | 696 |
| NCT05432388Peanut Hypersensitivity · United States | 2 | Completed | Mar 11, 2025 | 76 |
| NCT05156281Recurrence · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Jul 22, 2026 | 1,007 |
| NCT05147220Recurrence · United States, Argentina, Austria and more | 3 | Active, not recruiting | Jul 21, 2026 | 1,000 |
| NCT05048342Chronic Urticaria · Japan | 3 | Completed | Dec 8, 2023 | 71 |
| NCT05032157Chronic Urticaria · United States, Austria, Brazil and more | 3 | Completed | Dec 18, 2023 | 455 |
| NCT05030311Chronic Urticaria · United States, Argentina, Australia and more | 3 | Completed | Dec 27, 2023 | 470 |
| NCT04109313Chronic Urticaria · United States, Argentina, Belgium and more | 2 | Completed | Sep 9, 2022 | 229 |
| NCT04035668Sjogren's Syndrome · United States, Australia, Belgium and more | 2 | Terminated | Nov 23, 2021 | 73 |
| NCT03944707Asthma · United States, Argentina, Germany and more | 2 | Terminated | Apr 27, 2020 | 76 |
| NCT03926611Chronic Urticaria · United States, Argentina, Belgium and more | 2 | Completed | Jan 14, 2021 | 311 |
| NCT03827798Hidradenitis Suppurativa · United States, Austria, Belgium and more | 2 | Completed | Dec 4, 2024 | 248 |
| NCT03918980Dermatitis, Atopic · Germany, Netherlands | 1 | Completed | Jan 27, 2020 | 185 |
How it is read
Names in the registry
- “Remibrutinib”, 13 entries
- “LOU064”, 7 entries
- “LOU064 (blinded)”, 3 entries
- “Remibrutinib Dose A”, 2 entries
- “Remibrutinib Dose B”, 2 entries
Conditions, from the studies’ own filings
- Chronic Urticaria, 12 studies
- Hidradenitis Suppurativa, 5 studies
- Pruritus, 2 studies
- Rosacea, 1 study
- Food Hypersensitivity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.